New SEC filings from pharmaceutical companies reveal Donald Trump and Elon Musk’s cost-cutting measures could slow drug research and delay FDA approvals.
Trump’s FDA Cuts Are Putting Drug Development at Risk from Caroline Haskins

New SEC filings from pharmaceutical companies reveal Donald Trump and Elon Musk’s cost-cutting measures could slow drug research and delay FDA approvals.